Keywords: Breast, Breast
Motivation: Triple-negative breast cancer (TNBC) is more aggressive than other molecular subtypes, and finding new biomarkers for targeted therapy and stratification of progression risk would be helpful.
Goal(s): To evaluate MRI features between HER2-zero and HER2-low, and between progressed vs. non-progressed TNBC patients.
Approach: MRI features were reviewed by radiologists based on BI-RADS lexicon.
Results: 85/126 (67%) were identified as HER2-zero and 41 (33%) as HER2-low. No MRI features showed a significant difference between HER2-zero vs HER2-low. Fourteen of 126 (11%) patients showed progression (local, regional progression or distant metastasis), and they have more aggressive finding features and higher stages.
Impact: TNBC had negative ER, PR, and HER2, which was defined as immunohistochemical staining 0, 1+, or 2+ with negative FISH, but currently, HER2-low may receive anti-HER2 drug conjugates. Finding imaging biomarkers may help in precision treatment and understanding progression risk.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords